Ocata Therapeutics, Inc.

Sentiments around the 2023 biopharma dealmaking environment may be mixed, but Mike Luther, the global head of search and evaluation business development at Astellas Pharma, Inc. , hopes the coming ye

Following the conclusion within the past 20 months of two major deals in oncology potentially worth close to $13bn, Daiichi Sankyo Co., Ltd. is reorganizing its global structure in this disease area

Astellas Pharma Inc. is paying $65m upfront to expand its ongoing R&D collaboration with Cytokinetics Inc. for skeletal muscle activator drugs to include new programs and assets for amyotrophic

Daiichi Sankyo Co. Ltd. 's move to jump-start its pipeline in the regenerative medicine area by acquiring rights in Japan to a novel cell therapy continues a trend for pharma majors in the country to